NIH launches COVID‑style public‑private push for personalized cancer vaccines
The National Institutes of Health announced a public‑private partnership to accelerate personalized cancer‑vaccine development, slated to begin in December. The program will target pancreatic, liver, colorectal cancers and a subset of pediatric tumors. Moderna and Merck’s joint mRNA melanoma vaccine (V940) showed positive Phase 3 results in a trial of 1,137 patients, fueling investor enthusiasm.
Why it matters
The announcement sparked a broad biotech rally, lifting Moderna shares about 14% and boosting peers such as Novavax, Vaxcyte and BioNTech. Investors are pricing in potential faster development timelines and new research collaborations for mRNA cancer therapies.
Key facts
- 1Moderna shares rose about 14% on October 9, reaching their highest level since January 2022. stocktwits.com
- 2The NIH‑led initiative is expected to launch in December. stocktwits.com
- 3The program will focus on pancreatic, liver, colorectal cancers and a subset of pediatric tumors. stocktwits.com
- 4Merck and Moderna’s personalized mRNA vaccine V940 was tested in a study of 1,137 advanced‑melanoma patients. stocktwits.com
- 5Novavax closed up about 16% near $13 following the report. stocktwits.com
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.